20 January 2025 - Positive reimbursement recommendations by Canada's Drug Agency and Institut National d'excellence en Santé et Services Sociaux.

Takeda Canada is pleased to announce that Health Canada has provided market authorisation for Fruzaqla (fruquintinib capsules), indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, an anti-EGFR agent (if RAS wild-type), and either trifluridine-tipiracil or regorafenib.

Read Takeda press release